Company Overview
Kamada Ltd. operates within the healthcare sector, specifically functioning as a drug manufacturer focused on specialty and generic pharmaceuticals. The company's core business involves the manufacturing and sale of plasma-derived protein therapeutics, which include KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for preventing cytomegalovirus disease in various organ transplants, and VARIZIG for post-exposure prophylaxis. As a publicly traded entity with the ticker KMDA, the firm currently maintains a market capitalization of $471.20M and employs a workforce of 462 individuals. With annual revenue reaching $180.46M, these financial metrics indicate that Kamada Ltd. holds a specific position in the plasma-derived therapeutics niche, serving a specialized market rather than a broad consumer base. The revenue figure reflects the total value of goods sold over the trailing twelve months, while the market cap suggests a valuation that investors assign based on future growth expectations relative to its current earnings and asset base.
Financial Health
The company reported revenue of $180.46M for the trailing twelve months, generating a net income of $20.20M and an EBITDA of $39.51M during the same period. The significant gap between the EBITDA of $39.51M and the net income of $20.20M reveals a substantial cost structure comprising interest expenses, taxes, and depreciation that reduces pre-tax earnings to the final bottom line. Kamada Ltd. generated free cash flow of $7.59M, which provides the company with financial flexibility to manage operations, service debt, or invest in manufacturing capabilities without relying solely on external financing. The firm's profitability is characterized by a gross margin of 42.3%, indicating that manufacturing costs consume less than half of the revenue before operating expenses are considered. Operating margins stand at 7.9%, while profit margins reach 11.2%, suggesting that after covering all operating and tax obligations, the company retains a modest portion of each sales dollar as profit. On the balance sheet, Kamada holds $75.47M in cash against total debt of $11.56M, resulting in a debt-to-equity ratio of 4.30, which indicates a leveraged position despite the high cash balance. The current ratio of 4.07 demonstrates strong short-term liquidity, as current assets are four times the value of current liabilities, providing a robust buffer against immediate obligations. Return on equity is reported at 7.6%, and return on assets is 4.4%, metrics that reveal how effectively management utilizes shareholder capital and total assets to generate earnings, though these returns are moderate relative to the firm's leverage.
Valuation Assessment
Valuation multiples for Kamada Ltd. show a trailing P/E ratio of 23.29 and a forward P/E of 13.74. The substantial difference between these two figures implies that the market expects earnings growth to accelerate significantly in the coming years, or conversely, that current earnings are elevated relative to future projections, necessitating a re-evaluation of the price-to-earnings spread. The price-to-book ratio stands at 1.75, indicating that the stock trades at a premium of 75% over its net asset value, which suggests investors value the company's intangible assets and future cash flows more than its tangible book equity. Alternative valuation metrics include a price-to-sales ratio of 2.61 and an EV/EBITDA of 10.28, which suggest the company is priced at a moderate multiple of its sales and enterprise value relative to earnings before interest, taxes, depreciation, and amortization. Regarding price volatility, the stock has a 52-week high of $9.35 and a 52-week low of $5.54, meaning the current price sits within this established trading range and reflects recent market sentiment fluctuations. The beta value of 0.30 indicates that the stock price exhibits low volatility relative to the broader market, moving with significantly less intensity than the overall equity index.
Growth & Income
The company's financial performance over the last year is defined by a revenue growth rate of 14.5% and an earnings growth rate of -14.1%. The divergence between these two figures implies that while top-line sales are expanding rapidly, earnings are contracting, likely due to non-recurring costs, one-time expenses, or a decline in margins that outpaces the growth in sales volume. Kamada Ltd. currently does not pay a dividend, evidenced by a dividend yield of 3.1% paired with a payout ratio of 0.0%, indicating that the company reinvests all of its earnings into growth initiatives, R&D, or balance sheet strengthening rather than distributing income to shareholders. This reinvestment strategy is common for specialty drug manufacturers aiming to expand their product pipeline or capture market share in the plasma-derived therapeutics sector. The overall growth and income profile for Kamada Ltd. is characterized by robust sales expansion in the absence of a dividend yield, with the market focusing on revenue trajectory and operational efficiency rather than income distribution.